| PRECLINICAL | evidence | Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions. | Wegovy | Liver health | 2026-04-01 |
| PRECLINICAL | evidence | Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Real-world experience of semaglutide 2.4 mg in the US: a retrospective analysis of profiles, satisfaction, and treatment patterns in people with obesity and overweight. | Semaglutide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide for obesity: a pill for every ill? | Semaglutide | — | 2026-03-31 |
| PRECLINICAL | evidence | Edible Marine Red Alga Gracilaria coronopifolia as a Potential Functional Ingredient: Chemical Profiling and Metabolic Effects in Diet-Induced Obese Rats. | Semaglutide | — | 2026-03-31 |
| PRECLINICAL | evidence | Wegovy: GPs to prescribe weight loss jab to prevent heart attacks and strokes. | Wegovy | — | 2026-03-31 |
| PRECLINICAL | evidence | GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs. | Semaglutide | — | 2026-03-30 |
| PRECLINICAL | evidence | Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials. | Semaglutide | — | 2026-03-30 |
| PRECLINICAL | evidence | Peripheral Eosinophilia in a Patient With Subacute Watery Diarrhea. | Semaglutide | — | 2026-03-30 |
| PRECLINICAL | evidence | Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review. | Semaglutide | — | 2026-03-30 |
| PRECLINICAL | evidence | Prevalence of Obesity Medications in the Military Health System: An Update from 2022. | Wegovy | — | 2026-03-27 |
| PRECLINICAL | evidence | Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia. | Semaglutide | — | 2026-03-26 |
| PRECLINICAL | evidence | Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis. | Semaglutide | — | 2026-03-26 |
| PRECLINICAL | evidence | Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. | Semaglutide | Glycemic control | 2026-03-25 |
| PRECLINICAL | evidence | Media Coverage of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) After Semaglutide Use: A Content Analysis of News Reporting Accuracy and Framing. | Semaglutide | — | 2026-03-24 |
| PRECLINICAL | evidence | Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus. | Semaglutide | — | 2026-03-23 |
| PRECLINICAL | evidence | Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats. | Semaglutide | — | 2026-03-23 |
| PRECLINICAL | evidence | Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. | Semaglutide | Glycemic control | 2026-03-23 |
| PRECLINICAL | evidence | A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. | Semaglutide | — | 2026-03-23 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. | Semaglutide | — | 2026-03-21 |
| PRECLINICAL | evidence | The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives. | Semaglutide | — | 2026-03-20 |
| PRECLINICAL | evidence | Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis. | Semaglutide | — | 2026-03-20 |
| PRECLINICAL | evidence | Semaglutide and Alcohol use Disorder: Breaking Free of Addiction? | Semaglutide | — | 2026-03-18 |
| PRECLINICAL | evidence | Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review. | Semaglutide | — | 2026-03-18 |
| PRECLINICAL | evidence | New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication. | Ozempic | Weight & fat loss | 2026-03-18 |
| PRECLINICAL | evidence | First Experience With Semaglutide for the Treatment of Obesity in Nondiabetic Patient With Progressive Dysfunction of Renal Graft. | Semaglutide | — | 2026-03-17 |
| PRECLINICAL | evidence | Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials. | Semaglutide | — | 2026-03-17 |
| PRECLINICAL | evidence | Correction. | Ozempic | — | 2026-03-16 |
| PRECLINICAL | evidence | Losing Weight and Gaining Wrinkles: The Impact of Weight Loss Drugs on Facial Aesthetics. | Semaglutide | — | 2026-03-16 |
| PRECLINICAL | evidence | Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. | Semaglutide | Glycemic control | 2026-03-14 |
| PRECLINICAL | evidence | Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study. | Semaglutide | Glycemic control | 2026-03-14 |
| PRECLINICAL | evidence | GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. | Semaglutide | Weight & fat loss | 2026-03-13 |
| PRECLINICAL | evidence | Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials. | Semaglutide | Glycemic control | 2026-03-13 |
| PRECLINICAL | evidence | ARPA-H bets big to foster drugs that thwart aging. | Semaglutide | Longevity & cellular aging | 2026-03-12 |
| PRECLINICAL | evidence | Altered Mental Status Due to Amantadine Withdrawal: A Case Report. | Semaglutide | — | 2026-03-12 |
| PRECLINICAL | evidence | Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review. | Semaglutide | Glycemic control | 2026-03-11 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations. | Semaglutide | — | 2026-03-11 |
| PRECLINICAL | evidence | Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing's syndrome: a multicenter retrospective study. | Semaglutide | Glycemic control | 2026-03-10 |
| PRECLINICAL | evidence | AI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis. | Semaglutide | — | 2026-03-10 |
| PRECLINICAL | evidence | Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage. | Semaglutide | — | 2026-03-10 |
| PRECLINICAL | evidence | Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure. | Semaglutide | Weight & fat loss | 2026-03-10 |
| PRECLINICAL | evidence | Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG? | Semaglutide | — | 2026-03-09 |
| PRECLINICAL | evidence | AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework. | Ozempic | — | 2026-03-09 |